Prothena to Report Second Quarter 2021 Financial Results on August 5th
DUBLIN, Ireland, July 29, 2021 – Prothena Corporation plc (NASDAQ:PRTA) will release its second quarter and first half of 2021 financial results on August 5, 2021, after U.S. market close.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
DUBLIN, Ireland, July 29, 2021 – Prothena Corporation plc (NASDAQ:PRTA) will release its second quarter and first half of 2021 financial results on August 5, 2021, after U.S. market close. The company, known for its investigational therapeutics targeting protein dysregulation associated with rare peripheral amyloid and neurodegenerative diseases, will not hold a conference call for this release. Prothena aims to advance its pipeline, which includes treatments for AL amyloidosis, ATTR amyloidosis, Alzheimer's, and Parkinson's diseases.
Positive
- Upcoming financial results release on August 5, 2021, may provide insights into company performance.
Negative
- No conference call scheduled, limiting investor engagement post-results.
Details
News Market Reaction – PRTA
The recorded move for PRTA in the trading session of this news was +0.76%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
DUBLIN, Ireland, July 29, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with a robust pipeline of novel investigational therapeutics built on protein dysregulation expertise, announced today that it will report its second quarter and first six months of 2021 financial results on Thursday, August 5, 2021 after the close of the U.S. financial markets.
Consistent with past practice, the Company will not be conducting a conference call in conjunction with this financial results release on August 5.
About Prothena
Prothena Corporation plc is a late-stage clinical company with a robust pipeline of novel investigational therapeutics built on protein dysregulation expertise with the potential to change the course of devastating rare peripheral amyloid and neurodegenerative diseases. Fueled by its deep scientific expertise built over decades of research, Prothena is advancing a pipeline of therapeutic candidates for several indications and novel targets for which its ability to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins can be leveraged. Prothena’s pipeline includes both wholly-owned and partnered programs being developed for the potential treatment of diseases including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and a number of other neurodegenerative diseases. For more information, please visit the Company’s website at www.prothena.com and follow the Company on Twitter @ProthenaCorp.
Media & Investors:
Jennifer Zibuda, Director, Investor Relations & Communications
650-837-8535, jennifer.zibuda@prothena.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.